From a financial standpoint, someone is ultimately footing the bill, and right now there are very few answers about what happens after December 31, 2027. Alex Beene, a financial literacy instructor for the University of Tennessee at Martin, also told the outlet, The greatest concern is that while in the short-term the program could provide health benefits to those who need help with weight management, in the long-term, those same problems could return if there is a failure to extend the program past its current end date. How to enroll in the Medicare GLP-1 Bridge program To enroll in the Medicare GLP-1 Bridge program and get access to certain GLP-1 drugs at a discounted rate, Medicare Part D participants must speak to their providers on or after July 1
The course currently covers Foundayo (orforglipron, Eli Lilly), which received FDA approval in April 2026, as well as oral Wegovy tablets (oral semaglutide, approved December 2025)
While incretin-based therapies have been commercially available since 2005, most clinical trials only report short term outcomes
It was meant to rule out deficiency, but the result points the other direction
Porkolb G, Mszros M, Tth A, Szecsk A, Harazin A, Szegletes Z, et al
Quicksilver's delivery system is the reason this costs more than capsule glutathione